CURE15h
How Antibody-Drug Conjugates Have Impacted HER2-Positive Breast Cancer Treatment
Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.
CURE16h
FDA Approves Keytruda in HER2+ Gastric, Gastroesophageal Junction Cancer
The FDA has approved Keytruda plus chemotherapy in HER2+ gastric or GEJ adenocarcinoma with PD-L1–positive expression, based on KEYNOTE-811 data.
Targeted Oncology17h
FDA Grants Orphan Drug Designation to HLX22 for Gastric Cancer Treatment
The FDA granted orphan drug designation to HLX22 for gastric cancer, advancing global phase 3 trials to improve first-line ...
MPR15h
FDA Grants Traditional Approval to Keytruda for HER2+ Gastric/GEJ Cancer
When combined with trastuzumab and chemotherapy, treatment with pembrolizumab was associated with a statistically significant improvement in PFS and OS compared with placebo.
FDA grants traditional approval to Keytruda for HER2-positive GEJ
On March 19, the Food and Drug Administration granted traditional approval to pembrolizumab, or Keytruda, marketed by Merck (MRK), with ...
Labiotech.eu21h
Breast cancer treatments heat up: Five therapies poised to transform patient outcomes
Find out more about the overall breast cancer treatment landscape, as biotech companies make progress with different ...
The Manila Times22h
Henlius Receives Orphan Drug Designation for Innovative Anti-HER2 mAb HLX22 in the U.S. for Gastric Cancer
Shanghai Henlius Biotech, Inc. (2696.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for HLX22, the company's innovative anti-HER2 monoclonal ...